Overview

Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the INTREPiD study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (AL) against usual antenatal care on a composite adverse pregnancy outcome including low birth weight, small for gestational age, preterm, fetal loss, or neonatal death.

Phase:

Phase 4

Details

Lead Sponsor:

Duke University

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Artemether
Artemether, Lumefantrine Drug Combination
Lumefantrine